Ert Pompe denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for ert pompe are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies ERT for Pompe Disease as Duplicate Therapy

A duplicate-therapy denial means UnitedHealthcare's system flagged that another enzyme replacement therapy (ERT) for Pompe disease is already active or recently dispensed on your account. Because only a small number of ERTs are approved for Pompe disease, the plan may assume you are being billed for the same therapeutic class twice — even when a treating clinician has intentionally transitioned you from one agent to another, or when a hospital infusion and an outpatient claim overlap in timing.

## Why This Denial Is Appealable

Duplicate-therapy flags are almost always administrative errors. If your physician changed your ERT (for example, switching between approved agents due to efficacy or tolerability), that is a clinically sanctioned transition, not a duplicate. Similarly, a crossover period during a transition — where both agents briefly appear in claims data — does not mean you are receiving identical treatment concurrently. The denial does not reflect a clinical judgment about appropriateness; it reflects a billing rule mismatch.

## Federal Appeal Framework

You have layered federal protections:

• ERISA §503 (if your plan is employer-sponsored) guarantees a full-and-fair internal review with a written explanation of the denial reasons.
• ACA §2719 entitles you to an independent external review by an accredited Independent Review Organization (IRO) after exhausting internal appeals. The external-review window is generally within approximately four months of the denial notice — confirm the exact deadline on your Explanation of Benefits.
• Expedited review is available if your condition is urgent or if a standard timeline would seriously jeopardize your health.

## Concrete Appeal Steps

1. Request the full denial letter and the plan's published coverage policy for ERT in Pompe disease. 2. File an internal appeal within the deadline shown on the denial notice (typically 180 days for ERISA plans). 3. If the internal appeal is denied, immediately request external review — do not wait.

## Documentation to Gather

• Diagnosis confirmation: Genetic test report confirming GAA pathogenic variants; enzyme assay results confirming acid alpha-glucosidase deficiency; physician diagnosis note.
• Treatment history with dates: Start and stop dates for any prior ERT agent, including the reason for transition (adverse reaction, suboptimal response, clinical deterioration).
• Clinical severity: Pulmonary function trend, motor function assessments, and any hospitalizations documented in the chart.
• Prescriber letter: A medical-necessity letter from your metabolic or neuromuscular specialist explaining that only one ERT is being actively administered, clarifying the transition timeline, and confirming this is not concurrent duplicate treatment.
• Claims reconciliation: Ask your infusion provider to supply itemized billing records with exact service dates to show there is no true overlap.

## Criteria-Mapping Structure

Pull the exact duplicate-therapy definition from UHC's published coverage policy for this drug class. For each stated criterion, document the specific chart fact that answers it:

| Policy Requirement | Your Chart Evidence | |---|---| | Only one ERT active at a time | Transition letter dated [date]; prior agent discontinued [date] | | Claims overlap explanation | Infusion center billing records showing single agent on each date of service |

Attach this table to your appeal letter so the reviewer can match every requirement to the evidence without interpretation.